Kaveri Pohlman
Stock Analyst at BTIG
(0.40)
# 3,157
Out of 4,667 analysts
22
Total ratings
23.53%
Success rate
-21.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Downgrades: Neutral | n/a | $3.21 | - | 4 | Aug 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $46 → $47 | $20.47 | +129.60% | 3 | Jun 27, 2024 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $20 → $30 | $12.22 | +145.50% | 2 | Apr 17, 2024 | |
| XNCR Xencor | Maintains: Buy | $56 → $38 | $24.10 | +57.68% | 1 | Apr 16, 2024 | |
| NUVB Nuvation Bio | Upgrades: Buy | $5 | $2.70 | +85.19% | 2 | Mar 26, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $62 | $46.50 | +33.33% | 1 | Mar 21, 2024 | |
| PYXS Pyxis Oncology | Initiates: Buy | $8 | $2.10 | +280.95% | 1 | Feb 9, 2024 | |
| EXEL Exelixis | Initiates: Buy | $27 | $34.83 | -22.48% | 1 | Dec 19, 2023 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $70 | $14.28 | +390.20% | 1 | Aug 23, 2023 | |
| STTK Shattuck Labs | Initiates: Buy | $12 | $1.01 | +1,088.12% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $8 | $0.87 | +823.25% | 2 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $1.16 | +8,520.69% | 1 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12,320 → $4,928 | $2.89 | +170,419.03% | 2 | Feb 9, 2022 |
MacroGenics
Aug 1, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.21
Upside: -
Genmab
Jun 27, 2024
Maintains: Buy
Price Target: $46 → $47
Current: $20.47
Upside: +129.60%
Cullinan Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $20 → $30
Current: $12.22
Upside: +145.50%
Xencor
Apr 16, 2024
Maintains: Buy
Price Target: $56 → $38
Current: $24.10
Upside: +57.68%
Nuvation Bio
Mar 26, 2024
Upgrades: Buy
Price Target: $5
Current: $2.70
Upside: +85.19%
Janux Therapeutics
Mar 21, 2024
Initiates: Buy
Price Target: $62
Current: $46.50
Upside: +33.33%
Pyxis Oncology
Feb 9, 2024
Initiates: Buy
Price Target: $8
Current: $2.10
Upside: +280.95%
Exelixis
Dec 19, 2023
Initiates: Buy
Price Target: $27
Current: $34.83
Upside: -22.48%
Arcus Biosciences
Aug 23, 2023
Reiterates: Buy
Price Target: $70
Current: $14.28
Upside: +390.20%
Shattuck Labs
Aug 31, 2022
Initiates: Buy
Price Target: $12
Current: $1.01
Upside: +1,088.12%
Jul 7, 2022
Maintains: Buy
Price Target: $16 → $8
Current: $0.87
Upside: +823.25%
Feb 24, 2022
Initiates: Buy
Price Target: $100
Current: $1.16
Upside: +8,520.69%
Feb 9, 2022
Maintains: Buy
Price Target: $12,320 → $4,928
Current: $2.89
Upside: +170,419.03%